These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 25684240)

  • 1. Oncology trial design: More accurately and efficiently advancing the field.
    Hohl RJ
    Clin Pharmacol Ther; 2015 May; 97(5):430-2. PubMed ID: 25684240
    [No Abstract]   [Full Text] [Related]  

  • 2. American Society of Clinical Oncology Developing First Clinical Trial.
    Brower V
    J Natl Cancer Inst; 2015 Nov; 107(11):djv356. PubMed ID: 26538625
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of nonrandomized trials in the evaluation of oncology drugs.
    Simon R; Blumenthal GM; Rothenberg ML; Sommer J; Roberts SA; Armstrong DK; LaVange LM; Pazdur R
    Clin Pharmacol Ther; 2015 May; 97(5):502-7. PubMed ID: 25676488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving evidence developed from population-level experience with targeted agents.
    McClellan MB; Daniel GW; Dickson D; Perlmutter J; Berger DP; Miller V; Nussbaum S; Malin J; Romine MH; Schilsky RL
    Clin Pharmacol Ther; 2015 May; 97(5):478-87. PubMed ID: 25676878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
    Dalmases A; Rojo F; Rovira A; Albanell J
    Med Clin (Barc); 2013 Aug; 141(4):176-80. PubMed ID: 23809407
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of Crossover in Oncology Clinical Trials on Evidence Levels in Early Benefit Assessment in Germany.
    Isbary G; Staab TR; Amelung VE; Dintsios CM; Iking-Konert C; Nesurini SM; Walter M; Ruof J
    Value Health; 2018 Jun; 21(6):698-706. PubMed ID: 29909875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project.
    Herbrand AK; Schmitt AM; Briel M; Diem S; Ewald H; Hoogkamer A; Joerger M; Mc Cord KA; Novak U; Sricharoenchai S; Hemkens LG; Kasenda B
    ESMO Open; 2019; 4(6):e000596. PubMed ID: 31803503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
    Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
    Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-of-1 trials in oncology.
    Collette L; Tombal B
    Lancet Oncol; 2015 Aug; 16(8):885-6. PubMed ID: 26248830
    [No Abstract]   [Full Text] [Related]  

  • 10. Introduction to special issue on biomarker-based clinical trial designs in oncology.
    Sargent DJ; Mandrekar S; Grothey A
    Chin Clin Oncol; 2015 Sep; 4(3):28. PubMed ID: 26408295
    [No Abstract]   [Full Text] [Related]  

  • 11. Selecting computer-based evidence sources.
    Wyatt JC; Vincent S
    Ann Oncol; 1999 Mar; 10(3):267-73. PubMed ID: 10355569
    [No Abstract]   [Full Text] [Related]  

  • 12. New Clinical Trial Designs Hasten Approvals for Targeted Therapies.
    Schmidt C
    J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26944760
    [No Abstract]   [Full Text] [Related]  

  • 13. Personalized Medicine: Genomics Trials in Oncology.
    Hayes DF; Schott AF
    Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression-free survival versus overall survival as the primary end point in anticancer drug trials: increasingly relevant impact of therapy following progression.
    Markman M
    Curr Oncol Rep; 2009 Jan; 11(1):1-2. PubMed ID: 19080733
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase 0 clinical trials in oncology: an exploratory methodology for constructing a study with patients undergoing surgery for metastatic disease.
    Pocard M; Soria JC; Aldaz-Carroll L; Bellet D
    J Clin Oncol; 2010 Oct; 28(30):4551-3. PubMed ID: 20837954
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluating Antiretroviral Therapy Initiation in HIV-Associated Malignancy: Is There Enough Evidence to Inform Clinical Guidelines?
    Oseso LN; Chiao EY; Bender Ignacio RA
    J Natl Compr Canc Netw; 2018 Aug; 16(8):927-932. PubMed ID: 30099368
    [No Abstract]   [Full Text] [Related]  

  • 17. Maurie Markman on the Groundbreaking TAPUR Trial.
    Markman M
    Oncology (Williston Park); 2017 Mar; 31(3):158, 168. PubMed ID: 28299751
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug therapy: Preclinical oncology - reporting transparency needed.
    Gardner EE; Rudin CM
    Nat Rev Clin Oncol; 2016 Jan; 13(1):8-9. PubMed ID: 26667971
    [No Abstract]   [Full Text] [Related]  

  • 19. Basket Trials in Oncology: A Trade-Off Between Complexity and Efficiency.
    Cunanan KM; Gonen M; Shen R; Hyman DM; Riely GJ; Begg CB; Iasonos A
    J Clin Oncol; 2017 Jan; 35(3):271-273. PubMed ID: 27893325
    [No Abstract]   [Full Text] [Related]  

  • 20. Oncology trials gear up for high-throughput sequencing.
    Mullard A
    Nat Rev Drug Discov; 2012 Apr; 11(5):339-40. PubMed ID: 22543457
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.